Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
VRAX Stock Forecast 2026-2027
$0.19
Current Price
$1.42M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to VRAX Price Targets
+423.6%
To High Target of $1.00
+423.6%
To Median Target of $1.00
+423.6%
To Low Target of $1.00
VRAX Price Momentum
-13.6%
1 Week Change
-9.5%
1 Month Change
-86.1%
1 Year Change
-45.7%
Year-to-Date Change
-87.9%
From 52W High of $1.58
+1.1%
From 52W Low of $0.19
📊 TOP ANALYST CALLS
Did VRAX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Virax Biolabs is one of their latest high-conviction picks.
Latest VRAX Stock Price Targets & Analyst Predictions
Based on our analysis of 1 Wall Street analyst, VRAX has a bullish consensus with a median price target of $1.00 (ranging from $1.00 to $1.00). The overall analyst rating is N/A (N/A/10). Currently trading at $0.19, the median forecast implies a 423.6% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yi Chen at HC Wainwright & Co., projecting a 423.6% upside. Conversely, the most conservative target is provided by Yi Chen at HC Wainwright & Co., suggesting a 423.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VRAX Analyst Ratings
1
Buy
0
Hold
0
Sell
VRAX Price Target Range
Low
$1.00
Average
$1.00
High
$1.00
Current: $0.19
Latest VRAX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VRAX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 9, 2026 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $1.00 |
| Mar 31, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Initiates | $3.00 |
Virax Biolabs Group Ltd. (VRAX) Competitors
The following stocks are similar to Virax Biolabs based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Virax Biolabs Group Ltd. (VRAX) Financial Data
Virax Biolabs Group Ltd. has a market capitalization of $1.42M with a P/E ratio of -0.1x. The company generates $2,986 in trailing twelve-month revenue with a -838.2% profit margin.
Revenue growth is -67.5% quarter-over-quarter, while maintaining an operating margin of -160,788.3% and return on equity of -83.8%.
Valuation Metrics
Market Cap
$1.42M
Enterprise Value
$-1,808,044
P/E Ratio
-0.1x
PEG Ratio
-0.8x
Price/Sales
499.5x
Growth & Margins
Revenue Growth (YoY)
-67.5%
Gross Margin
N/A
Operating Margin
-160,788.3%
Net Margin
-838.2%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+274.9%
Current Ratio
11.4x
Debt/Equity
10.6x
ROE
-83.8%
ROA
-48.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Virax Biolabs Group Ltd. (VRAX) Business Model
About Virax Biolabs Group Ltd.
What They Do
Develops diagnostic testing kits for viral diseases.
Business Model
Virax Biolabs generates revenue through the development and distribution of diagnostic testing kits aimed at the detection and management of viral infections. Its products cater to a wide range of clients, including healthcare institutions, government health departments, and research organizations, ensuring a steady demand across multiple sectors.
Additional Information
The company plays a significant role in public health, especially during global health crises, by providing essential tools for the early detection of viral pathogens. This focus on innovation in medical diagnostics positions Virax Biolabs as a key player in enhancing healthcare systems' capabilities to combat viral threats.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
19
CEO
Mr. James Foster
Country
United Kingdom
IPO Year
2022
Website
viraxbiolabs.comVirax Biolabs Group Ltd. (VRAX) Latest News & Analysis
Latest News
Quick Summary
Virax Biolabs Group Limited (VRAX) has been upgraded to a Zacks Rank #2 (Buy), indicating growing optimism about its earnings prospects.
Why It Matters
The upgrade to Zacks Rank #2 signals increased confidence in Virax Biolabs' earnings potential, suggesting potential stock price appreciation and attracting investor interest.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Virax Biolabs (NASDAQ: VRAX) is advancing its diagnostic technology for post-acute infection syndromes, including Long COVID, and anticipates significant data developments in 2026 following recent milestones.
Why It Matters
Virax Biolabs' advancements in diagnostic technology for Long COVID and other syndromes signal potential market growth and innovation, impacting future revenue and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Virax Biolabs has secured agreements to sell 12.5 million ordinary shares at $0.40 each, along with preferred options to purchase the same amount for five years.
Why It Matters
Virax's private placement of shares at $0.40 signals capital raising efforts, potentially diluting existing shares but funding growth in immunology, which may affect stock valuation and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Virax Biolabs secured $5 million in a private placement, extending its cash runway into H1 2028. This supports regulatory studies for COVID-19-related conditions and platform expansions.
Why It Matters
Virax Biolabs' extended cash runway into 2028 strengthens its financial stability, enabling continued development of key studies and partnerships, which could enhance its market position and growth potential.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Virax Biolabs has completed patient recruitment for its UK clinical study on the ViraxImmune™ assay, targeting T cell dysfunction in conditions like Long COVID, ahead of schedule with 160 participants.
Why It Matters
Successful completion of patient recruitment for the ViraxImmune™ assay study signals progress in addressing significant health issues, potentially boosting Virax's market position and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Virax Biolabs (NASDAQ: VRAX) has signed a Research Services Agreement with Emory University to conduct clinical studies on its ViraxImmune™ technology, targeting immune profiling in long COVID patients.
Why It Matters
The partnership with Emory University enhances Virax's credibility and potential for innovative treatments, which could drive stock value and attract investor interest in the biotech sector.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About VRAX Stock
What is Virax Biolabs Group Ltd.'s (VRAX) stock forecast for 2026?
Based on our analysis of 1 Wall Street analysts, Virax Biolabs Group Ltd. (VRAX) has a median price target of $1.00. The highest price target is $1.00 and the lowest is $1.00.
Is VRAX stock a good investment in 2026?
According to current analyst ratings, VRAX has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.19. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for VRAX stock?
Wall Street analysts predict VRAX stock could reach $1.00 in the next 12 months. This represents a 423.6% increase from the current price of $0.19. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Virax Biolabs Group Ltd.'s business model?
Virax Biolabs generates revenue through the development and distribution of diagnostic testing kits aimed at the detection and management of viral infections. Its products cater to a wide range of clients, including healthcare institutions, government health departments, and research organizations, ensuring a steady demand across multiple sectors.
What is the highest forecasted price for VRAX Virax Biolabs Group Ltd.?
The highest price target for VRAX is $1.00 from Yi Chen at HC Wainwright & Co., which represents a 423.6% increase from the current price of $0.19.
What is the lowest forecasted price for VRAX Virax Biolabs Group Ltd.?
The lowest price target for VRAX is $1.00 from Yi Chen at HC Wainwright & Co., which represents a 423.6% increase from the current price of $0.19.
What is the overall VRAX consensus from analysts for Virax Biolabs Group Ltd.?
The overall analyst consensus for VRAX is bullish. Out of 1 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $1.00.
How accurate are VRAX stock price projections?
Stock price projections, including those for Virax Biolabs Group Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 14, 2026 9:09 AM UTC